Reclassification of RAS/BRAF allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer.

Xiang ZhangHaizhong MaYinjun HeWenguang HeNan ChenYandong LiWeixiang ZhongGuosheng WuXile ZhouHanju HuaFeng YeMing Hu Weiqin Jiang

Published in: Therapeutic advances in medical oncology (2024)

G13D/G12V/G12C mutations collectively defined a high-risk subgroup of mCRC patients with poor prognosis, who would benefit from intensive triplet chemotherapy.

Keyphrases

metastatic colorectal cancer
poor prognosis
long non coding rna
locally advanced
energy transfer
wild type
randomized controlled trial
clinical trial
chemotherapy induced
radiation therapy
study protocol